Trials / Completed
CompletedNCT01944631
Iota-Carrageenan Nasal Spray in Common Cold
Efficacy and Safety of Iota-Carrageenan Nasal Spray 1.2 g/l (0.12 Percent) (Bisolviral) Versus Placebo Nasal Spray in the Early Treatment of Common Cold
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 200 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this clinical trial is to investigate the effect of Iota-Carrageenan treatment on cold symptoms. The effect of treatment on the duration of the cold and the patients viral load plus cytokine level indicating the inflammatory response will be analyzed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Placebo | Nasal spray saline |
| DEVICE | Iota-Carrageenan | Nasal spray containing 1.20 g/l Iota-Carrageenan in saline |
Timeline
- Start date
- 2013-09-01
- Primary completion
- 2014-03-01
- Completion
- 2014-03-01
- First posted
- 2013-09-17
- Last updated
- 2015-04-03
- Results posted
- 2015-04-03
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01944631. Inclusion in this directory is not an endorsement.